Proximity Ligation Assay for Protein-Protein Interaction Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarker strategies for cancer lack effective measures for protein-protein interactions (PPI) in cancer signaling networks, hindering personalized medicine approaches and the identification of responsive tumor subsets.
Innovation Solution
The use of proximity ligation assays (PLAs) to quantify protein-protein interactions (PPI) in cancer samples, allowing for the assessment of malignancy sensitivity to therapeutic interventions by measuring PPI profiles and identifying PPI modulators, such as inhibitors or inducers, to guide clinical decision-making.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If classic immunohistochemistry approaches and proteomic profiling tools are used to measure protein expression, then protein expression levels can be determined, but protein-protein interaction information is lost
Solution Approach 1:
The patent introduces proximity ligation assays as an intermediary technique that bridges the gap between traditional protein expression measurement and PPI detection. The PLA method uses paired antibodies and oligonucleotide-ligated proximity probes as mediators to detect and quantify protein-protein interactions while maintaining compatibility with standard immunohistochemistry workflows, thereby recovering the lost PPI information without sacrificing expression level data.
2Reliability
If PPI biomarkers are implemented to guide personalized medicine, then treatment responsiveness can be accurately assessed, but device complexity and assay requirements increase
Solution Approach 1:
The patent designs a universal PPI detection platform using proximity ligation assays that can measure multiple different protein-protein interactions through a standardized workflow. The same basic PLA methodology and detection system can be applied to various cancer types and therapeutic contexts, reducing the need for separate complex assays for each specific PPI measurement and enabling broad application across personalized medicine scenarios.
3Adaptability or versatility
If quantitative PPI measurement is implemented to identify responsive tumor subsets, then personalized treatment selection is improved, but loss of time and resource intensity increase
Solution Approach 1:
The patent employs preliminary action by performing PPI profiling on archival tissue samples and establishing baseline PPI signatures before treatment decisions are made. The proximity ligation assays can be performed on fixed tissue samples that are already available from routine pathology workflows, eliminating the need for additional fresh sample collection and preparation time. This allows PPI data to be integrated into existing diagnostic timelines without adding significant delays to treatment planning.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the identification of sensitive malignancies to specific treatments, optimizing therapy by determining the presence and proximity of target binding partners within cancer PPI networks, thereby improving treatment efficacy and reducing unnecessary therapy administration.
Implementation Method 1
the nucleic acid strands (through the addition of two circle-forming oligonucleotides) become ligated together by enzymatic ligation and form a circle that functions as a template for amplification
Implementation Method 2
After the amplification reaction, the resulting rolling circular amplification (RCA) serves as a target for labeled (e.g., fluorescently labeled) complimentary oligonucleotide probes
Implementation Method 3
the resulting rolling circular amplification (RCA) serves as a target for labeled (e.g., fluorescently labeled) complimentary oligonucleotide probes, which allow for detection (e.g., visualization) and quantification of the product
Data Source
AI summary
The subject invention pertains to materials and methods for the classification of cancers as sensitive or resistant to treatments based on protein-protein interactions, treatment of cancer, identification of biomarkers, identification of protein-protein interaction modulators, and selection of cancer treatments.